Study of Intranasal Clonazepam in Adult Subjects With Epileptic Seizures
NCT ID: NCT00594945
Last Updated: 2014-07-01
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
45 participants
INTERVENTIONAL
2007-12-31
2009-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray.
NCT02316847
Effects of Clobazam on Sleep and Daytime Function in Patients With Epilepsy
NCT02911025
A Pharmacokinetic Study of a Single-Dose of Diazepam Nasal Spray in Adult Epileptic Patients Experiencing a Seizure Episode
NCT01417078
A Study of Diazepam After Intranasal and Intravenous Administration to Healthy Volunteers
NCT01364558
Benzodiazepine Study for the Treatment of Seizure Clusters in a Third Level Mexican Neurological Center
NCT06056349
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intranasal Clonazepam 2 mg
Clonazepam
1 Dose
Intranasal Clonazepam 3 mg
Clonazepam
1 Dose
Intranasal Clonazepam both Dose Groups 2 mg & 3 mg
Clonazepam
1 Dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Clonazepam
1 Dose
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No Nasal conditions that would preclude the use of intranasal product
Exclusion Criteria
* Subject currently or regularly taking Clonazepam
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jazz Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Beverly Benson, PhD
Role: STUDY_DIRECTOR
Jazz Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Trials. inc.
Little Rock, Arkansas, United States
Mid-Atlantic Epilepsy & Sleep Center
Bethesda, Maryland, United States
Columbia Comprehensive Epilepsy Center, Neurological Institute
New York, New York, United States
Ohio State University
Columbus, Ohio, United States
Neurological Clinic of Texas, PA
Dallas, Texas, United States
Tampere University Hospital
Tampere, , Finland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
07-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.